Oscar Health (OSCR) Stock Surges 13% on Wells Fargo Upgrade and Price Target Increase

Key Takeaways

• Wells Fargo shifted its rating on OSCR to Equal Weight from Underweight, increasing the price target from $11 to $20
• Shares were trading around $20.50, marking a 43% gain year-to-date
• In Florida, which represents approximately 64% of premiums, membership declined 13.5% year-over-year while medical loss ratios strengthened by 370 basis points
• First quarter 2026 earnings per share reached $2.07, significantly exceeding the $1.06 consensus estimate
• Wall Street sentiment has grown more positive on 2026 prospects, though uncertainty persists beyond the current year

Shares of Oscar Health (OSCR) experienced a significant rally on Wednesday following an analyst upgrade from Wells Fargo that included a substantial price target revision, propelling the health insurance company’s stock up approximately 14% during the trading session.

Oscar Health, Inc., OSCR

Wells Fargo’s Stephen Baxter revised his stance on OSCR, upgrading the stock from Underweight to Equal Weight while elevating the price target from $11 to $20. At the time of the announcement, shares were changing hands near the $20.50 level.

The rating adjustment followed Wells Fargo’s examination of statutory regulatory filings, which revealed that both enrollment figures and morbidity trends across health insurance exchanges are performing better than anticipated heading into 2026.

The broader industry is demonstrating significant improvement in medical loss ratios, and insurance companies appear to be taking a more conservative approach to risk adjustment accounting compared to the previous year — a development Wells Fargo interprets favorably.

Baxter noted that the firm has gained greater confidence in the exchange market’s direction for 2026, while acknowledging that long-term visibility remains limited. Payment integrity continues to be monitored as a critical factor going forward.

Performance in the Florida Market

Florida represents Oscar’s largest geographic market, contributing approximately 64% of total premium revenue. While enrollment in the state fell 13.5% compared to the prior year, the medical loss ratio showed improvement of 370 basis points during the same timeframe.

Wells Fargo identified potentially 640 basis points of conservative positioning in Oscar’s risk adjustment accounting methodology for Florida — a contrast to the dynamics observed in the previous year.

Prior to Wednesday’s upgrade announcement, Oscar had already accumulated a 43% gain year-to-date, with shares trading near $20.50 before the news drove prices higher.

Despite the strong upward movement, the stock experienced some volatility throughout the session. Market participants appeared to be balancing the unclear outlook beyond 2026 against the more favorable near-term operating environment.

First Quarter Performance and Executive Transition

Oscar delivered first quarter 2026 earnings per share of $2.07, substantially surpassing the analyst consensus of $1.06. Revenue figures, however, fell short of expectations during the quarter.

Analyst projections indicate Oscar Health will achieve full-year profitability in 2026, with three analysts having recently increased their earnings forecasts.

On the executive front, co-founder Mario Schlosser transitioned away from his operational roles as President of Technology and Chief Technology Officer. He has assumed a position as Co-Founder and Advisor to the CEO, where he will focus on the company’s artificial intelligence and digital health initiatives while maintaining his board seat.

The company currently maintains a market capitalization of approximately $6.37 billion. Daily trading volume averages around 7.16 million shares.

Wells Fargo’s upgrade reflects a wider pattern among analysts adopting a more optimistic view of Oscar’s near-term prospects based on preliminary 2026 exchange market performance data.